Cardan Health has increased its annual profit forecast to between $10.7 and $11.8 per share, up from its previous estimate of $10.,15 per share. The company is benefiting from strong demand for high-margin medicines for complex conditions such as cancer and autoimmune diseases, as well as the rollout of biosimilars for blockbuster drugs that have lost their patent protection. Drug distributors such as Cardinal Health, Cencora, and McKesson have been expanding their presence in specialty medicines through acquisitions of physician practices and care networks. The pharmaceutical and specialty solutions unit, which distributes branded and generic drugs, saw sales of $56.1 billion, up 11% year-over-year, in the third quarter.